Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Transparency <strong>Market</strong><br />
Research<br />
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> - <strong>Global</strong> <strong>Industry</strong><br />
<strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>, <strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong>,<br />
<strong>2013</strong> - <strong>2019</strong><br />
Published Date<br />
<strong>2013</strong>-10-21<br />
98 Page Report<br />
Buy Now<br />
Request Sample<br />
Press Release<br />
Patent Expirations in <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Result in a<br />
Decline at 4.5% CAGR<br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90, State Street, Suite 700.<br />
Albany, NY 12207<br />
United States<br />
www.transparencymarketresearch.com<br />
sales@transparencymarketresearch.com
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
REPORT DESCRIPTION<br />
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> - <strong>Global</strong> <strong>Industry</strong> <strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>,<br />
<strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong>, <strong>2013</strong> <strong>–</strong> <strong>2019</strong><br />
In a new report titled ‘<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> - <strong>Global</strong> <strong>Industry</strong> <strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>,<br />
<strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong>, <strong>2013</strong> - <strong>2019</strong>,’ published by Transparency <strong>Market</strong> Research, research<br />
analysts state that the global erectile dysfunction drugs market is expected to decline at a CAGR<br />
of 4.5% in the forecast period <strong>2013</strong> to <strong>2019</strong>. This market was valued at US$4.3 billion in 2012 but<br />
is, however, expected to reach an estimated value of US$3.4 billion in <strong>2019</strong>.<br />
<strong>Erectile</strong> dysfunction is a very common medical disorder in men. It typically affects men older<br />
than 40 years in age <strong>and</strong> can be postulated as an age-related condition too. But at some point in<br />
time, men may also face erectile dysfunction due to psychological <strong>and</strong> physiological factors.<br />
According to the research led by the analysts at TMR, the global erectile dysfunction drugs<br />
market is mainly driven by a rise in incidences of various diseases, rising geriatric population,<br />
increasing focus on awareness <strong>and</strong> education, <strong>and</strong> shifting preference towards a sedentary<br />
lifestyle.<br />
Browse the full <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Report @ :<br />
http://www.transparencymarketresearch.com/erectile-dysfunctiondrugs.html<br />
Moreover, the growing impact of clinical tests <strong>and</strong> trials for erectile dysfunction drugs contributes<br />
vastly to the growth in the erectile dysfunction drugs market. Some other areas that hold plenty<br />
of growth opportunities in this market are innovative drug delivery, blockbuster patent<br />
expirations, new test techniques, <strong>and</strong> molecule combinations.<br />
Three major erectile dysfunction drugs - Cialis (tadalafil), Viagra (sildenafil citrate), <strong>and</strong><br />
Levitra/Staxyn (vardenafil) <strong>–</strong> have been studied in this research report. Some more br<strong>and</strong>ed<br />
Transparency <strong>Market</strong> Research<br />
2
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
drugs such as MUSE (medicated urethral systems for erection), Stendra/Spedra (avanafil),<br />
Zydena (udenafil), Mvix (mirodenafil) <strong>and</strong> Helleva (lodenafil) have also been covered in this<br />
study.<br />
Browse the full <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> press release @ :<br />
http://www.transparencymarketresearch.com/pressrelease/erectiledysfunction-<br />
drugs.htm<br />
By revenue, Viagra (sildenafil citrate) accounted for the largest share <strong>–</strong> 45% of the total erectile<br />
dysfunction drugs market. But due to the expiration of patents of the Viagra drug particularly<br />
outside the U.S. in <strong>2013</strong>, <strong>and</strong> also due to the loss of patent <strong>and</strong> marketing exclusivity of Levitra<br />
(vardenafil) by Bayer AG <strong>and</strong> Cialis (tadalafil) by Eli Lilly & Co. in Europe <strong>and</strong> many other<br />
countries, the overall market revenue is likely to decline over the forecast period.<br />
The market for Cialis (tadalafil) will also witness a decline in market revenue from <strong>2013</strong> to <strong>2019</strong>.<br />
This market had accounted for the second largest share in 2012, at US$1,926.8 million, but is<br />
now declining at a CAGR of 12.6% in the forecast period.<br />
Get Free Sample Report <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>:<br />
http://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=S&rep_id=1550<br />
The dem<strong>and</strong> for erectile dysfunction drugs is continuously rising to cater to the needs of the<br />
increasing elderly population <strong>and</strong> other growing diseases including renal diseases, chronic<br />
disorders, hypertension, hormonal insufficiency, diabetes, <strong>and</strong> other neurological disorders.<br />
Transparency <strong>Market</strong> Research<br />
3
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
<strong>Forecast</strong>s state that by the end of <strong>2019</strong>, the erectile dysfunction drugs market is expected to<br />
witness a major decline in the world. Owing to weak pipeline development the erectile<br />
dysfunction drugs market will experience a low success rate in the matters of new drug<br />
formulations as well.<br />
Geographically, the North American market for erectile dysfunction drugs was valued at<br />
US$2,098.4 million in 2012 <strong>and</strong> is expected to continue to lead throughout the forecast period in<br />
terms of revenue generation.<br />
TABLE OF CONTENT<br />
Chapter 1 Preface<br />
1.1 Report Description<br />
1.2 <strong>Market</strong> Segmentation<br />
1.3 Research Methodology<br />
1.4 List of Abbreviations<br />
Chapter 2 Executive Summary<br />
Chapter 3 <strong>Market</strong> Overview<br />
3.1 Introduction to <strong>Erectile</strong> <strong>Dysfunction</strong><br />
3.2 Current <strong>Market</strong> <strong>Trends</strong> <strong>and</strong> Future Outlook<br />
3.2.1 Impact of Generics<br />
Transparency <strong>Market</strong> Research<br />
4
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.2.2 Key Patent Expirations<br />
3.2.3 Ongoing Clinical Trials in the U.S. for ED Treatment (Phase III)<br />
3.3 Types of Treatments for ED<br />
3.3.1 Phosphodiesterase Type 5 Inhibitors (PDE 5 Inhibitors)<br />
3.3.2 Localized Therapy<br />
3.3.3 Testosterone Replacement Therapy<br />
3.3.4 Vacuum Constriction Devices<br />
3.3.5 Surgery (Penile Implants <strong>and</strong> Vascular Surgery)<br />
3.3.6 Alternative Medicines (Yohimbine <strong>and</strong> Other Herb <strong>and</strong> Dietary Supplements)<br />
3.4 <strong>Market</strong> Drivers<br />
3.4.1 Increase in Elderly Population<br />
Lifestyle<br />
3.4.2 Increasing <strong>Global</strong> Incidence of Various Diseases <strong>and</strong> Growing Preference Towards Sedentary<br />
3.4.3 Increase in Awareness <strong>and</strong> Patient Education<br />
3.5 <strong>Market</strong> Restraints<br />
3.5.1 Prevalence of Sexually Transmitted Diseases with ED Drug Users<br />
3.5.2 Narrowing of Insurance Coverage for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment<br />
3.5.3 Growing Threat from Counterfeit <strong>Drugs</strong><br />
3.6 <strong>Market</strong> Opportunities<br />
3.6.1 Novel Molecule Combinations <strong>and</strong> Drug Delivery Techniques are Expected to Become a Rising<br />
Opportunity<br />
Transparency <strong>Market</strong> Research<br />
5
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.6.2 Generics - A Growing <strong>Global</strong> Opportunity<br />
3.7 Porter’s Five Forces <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.7.1 Bargaining Power of Suppliers<br />
3.7.2 Bargaining Power of Buyers<br />
3.7.3 Threat of Substitutes<br />
3.7.4 Threat of New Entrants<br />
3.7.5 Competitive Rivalry<br />
3.8 <strong>Market</strong> Attractiveness <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography (2015)<br />
Chapter 4 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, By Br<strong>and</strong>, 2011-<strong>2019</strong> (USD Million)<br />
4.1 <strong>Market</strong> Overview<br />
4.1.1 Mechanism of Action<br />
4.1.2 Characteristics of Major Phosphodiesterase Type 5 Inhibitors<br />
4.2 Viagra (Sildenafil Citrate)<br />
4.2.1 Introduction<br />
4.2.2 <strong>Global</strong> Viagra <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.2.3 Patent Expiration <strong>and</strong> Regulatory Scenario<br />
4.2.3.1 The U.S. <strong>Market</strong><br />
4.2.3.2 International <strong>Market</strong><br />
4.2.4 Past & Current <strong>Market</strong> Scenario<br />
4.2.5 <strong>Global</strong> Viagra <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
6
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.2.6 Future <strong>Market</strong> Scenario<br />
4.2.7 <strong>Global</strong> Viagra <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.3 Cialis (Tadalafil)<br />
4.3.1 Introduction<br />
4.3.2 <strong>Global</strong> Cialis <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.3.3 Patent <strong>and</strong> Regulatory Scenario<br />
4.3.4 Current <strong>Market</strong> Scenario <strong>and</strong> Patent Expiry Effect<br />
4.3.5 <strong>Global</strong> Cialis <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
4.3.6 Future <strong>Market</strong> Scenario<br />
4.3.7 <strong>Global</strong> Cialis <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.4 Levitra/Staxyn (Vardenafil)<br />
4.4.1 Introduction<br />
4.4.2 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.4.3 Patent <strong>and</strong> Regulatory Scenario<br />
4.4.4 Current <strong>and</strong> Future <strong>Market</strong> Scenario<br />
4.4.5 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
4.4.6 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.5 Stendra/Spedra (Avanafil)<br />
4.5.1 Introduction<br />
4.5.2 Future <strong>Market</strong> Scenario<br />
4.5.3 <strong>Global</strong> Stendra/Spedra <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
7
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.6 Zydena (Udenafil)<br />
4.6.1 Introduction<br />
4.6.2 <strong>Global</strong> Zydena <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.6.3 Current <strong>Market</strong> Scenario<br />
4.6.4 <strong>Global</strong> Zydena <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
4.6.5 Future <strong>Market</strong> Scenario<br />
4.6.6 <strong>Global</strong> Zydena <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
4.7 MUSE (Medicated Urethral System for Erection)<br />
4.7.1 Patent <strong>and</strong> Regulatory Scenario<br />
4.8 Mvix (Mirodenafil)<br />
4.9 Helleva (Lodenafil Carbonate)<br />
Chapter 5 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, Pipeline <strong>Analysis</strong><br />
5.1 Overview<br />
5.2 Vitaros (Alprostadil)<br />
5.2.1 <strong>Global</strong> Vitaros <strong>Market</strong> for <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2014 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
5.3 Uprima (Apomorphine)<br />
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)<br />
5.4.1 Topiglan<br />
5.4.2 Melanocortin Activators<br />
5.4.3 Gene Therapy<br />
Transparency <strong>Market</strong> Research<br />
8
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Chapter 6 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography<br />
6.1 Overview<br />
6.1.1 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, By Geography, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
(Value %)<br />
6.1.2 Comparative <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography, 2012 & <strong>2019</strong><br />
6.2 North America<br />
6.2.1 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
6.2.2 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
6.3 Europe<br />
6.3.1 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
6.3.2 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
6.4 Asia-Pacific<br />
6.4.1 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
6.4.2 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
6.5 Rest of the World (Row)<br />
6.5.1 Rest of the World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
6.5.2 Rest of the World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
Chapter 7 Competitive L<strong>and</strong>scape<br />
7.1 <strong>Market</strong> <strong>Share</strong> <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2012 (%)<br />
Transparency <strong>Market</strong> Research<br />
9
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
7.1.1 Methodology<br />
7.1.2 <strong>Analysis</strong><br />
Chapter 8 Recommendations<br />
8.1 Novel Drug Formulations <strong>and</strong> Genericization owing to Patent Expiration of well recognized ED <strong>Drugs</strong><br />
8.2 Mergers <strong>and</strong> Acquisitions to Strengthen <strong>Market</strong> Presence<br />
8.3 Cost Containment Measures<br />
Chapter 9 Company Profiles<br />
9.1 Apricus Biosciences, Inc.<br />
9.1.1 Company Overview<br />
9.1.2 Business Strategies<br />
9.1.3 Financial Overview<br />
9.1.4 Product Portfolio<br />
9.1.5 Recent Developments<br />
9.2 Bayer AG<br />
9.2.1 Company Overview<br />
9.2.2 Business Strategies<br />
9.2.3 Financial Overview<br />
9.2.4 Product Portfolio<br />
9.2.5 Recent Developments<br />
Transparency <strong>Market</strong> Research<br />
10
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
9.3 Cristalia Produtos Quimicos Farmaceuticos Ltda.<br />
9.3.1 Company Overview<br />
9.3.2 Business Strategies<br />
9.3.3 Product Portfolio<br />
9.3.4 Recent Developments<br />
9.4 Dong-A Pharmaceutical Co. Ltd.<br />
9.4.1 Company Overview<br />
9.4.2 Business Strategies<br />
9.4.3 Financial Overview<br />
9.4.4 Product Portfolio<br />
9.4.5 Recent Developments<br />
9.5 Eli Lilly And Company<br />
9.5.1 Company Overview<br />
9.5.2 Business Strategies<br />
9.5.3 Financial Overview<br />
9.5.4 Product Portfolio<br />
9.5.5 Recent Developments<br />
9.6 Meda Pharmaceuticals, Inc.<br />
9.6.1 Company Overview<br />
9.6.2 Business Strategies<br />
9.6.3 Product Portfolio<br />
Transparency <strong>Market</strong> Research<br />
11
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
9.6.4 Recent Developments<br />
9.7 Pfizer, Inc.<br />
9.7.1 Company Overview<br />
9.7.2 Business Strategies<br />
9.7.3 Financial Overview<br />
9.7.4 Product Portfolio<br />
9.7.5 Recent Developments<br />
9.8 S.K. Chemicals Co. Ltd.<br />
9.8.1 Company Overview<br />
9.8.2 Business Strategies<br />
9.8.3 Financial Overview<br />
9.8.4 Product Portfolio<br />
9.8.5 Recent Developments<br />
9.9 Vivus, Inc.<br />
9.9.1 Company Overview<br />
9.9.2 Business Strategies<br />
9.9.3 Financial Overview<br />
9.9.4 Product Portfolio<br />
9.9.5 Recent Developments<br />
List of Figures<br />
Transparency <strong>Market</strong> Research<br />
12
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 1 <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Segmentation<br />
FIG. 2 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, 2010 - <strong>2019</strong> (USD Million)<br />
FIG. 3 Porter’s Five Forces <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 4 <strong>Market</strong> Attractiveness <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography (2015)<br />
FIG. 5 PPDE 5 Inhibitors: Mechanism of Action<br />
FIG. 6 <strong>Global</strong> Viagra <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 7 <strong>Global</strong> Viagra <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 8 <strong>Global</strong> Viagra <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 9 <strong>Global</strong> Cialis <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 10 <strong>Global</strong> Cialis <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 11 <strong>Global</strong> Cialis <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 12 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 13 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 14 <strong>Global</strong> Levitra/Staxyn <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 15 <strong>Global</strong> Stendra/Spedra <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 16 <strong>Global</strong> Zydena <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 17 <strong>Global</strong> Zydena <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 18 <strong>Global</strong> Zydena <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 19 <strong>Global</strong> Vitaros <strong>Market</strong> For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2014 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 20 Comparative <strong>Analysis</strong>: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, By Geography, 2012 & <strong>2019</strong><br />
(Value %)<br />
Transparency <strong>Market</strong> Research<br />
13
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 21 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 22 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 23 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 24 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 25 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 26 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 27 Rest Of The World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 28 Rest Of The World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 29 <strong>Market</strong> <strong>Share</strong> By Key Players: Br<strong>and</strong>ed Formulations For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2012 (%)<br />
FIG. 30 Apricus Biosciences, Inc.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 31 Bayer AG: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 Euro = 1.35 USD)<br />
FIG. 32 Dong-A Pharmaceutical Co. Ltd.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 KRW = 0.0093 USD)<br />
FIG. 33 Eli Lilly & Co.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 34 Pfizer, Inc.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 35 S. K. Chemicals Co. Ltd.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 KRW = 0.0093 USD)<br />
List of Tables<br />
TABLE 1 <strong>Market</strong> Snapshot: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
TABLE 2 Causes Of <strong>Erectile</strong> <strong>Dysfunction</strong><br />
TABLE 3 Ongoing Clinical Trials In The U.S. For ED Treatment (Phase III)<br />
TABLE 4 Causes Of ED: Classes Of <strong>Drugs</strong> Used To Treat Chronic Diseases<br />
Transparency <strong>Market</strong> Research<br />
14
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
TABLE 5 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
TABLE 6 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong>, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
TABLE 7 Characteristics Of PDE 5 Inhibitor Class Of <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong><br />
TABLE 8 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, By Geography, 2010 <strong>–</strong> 2014 (USD Million)<br />
TABLE 9 <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong> Revenue, By Geography, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
Browse All Pharmaceutical <strong>Market</strong> Research Reports @<br />
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html<br />
About Us<br />
Transparency <strong>Market</strong> Research is a market intelligence company providing global business information<br />
reports <strong>and</strong> services. Our exclusive blend of quantitative forecasting <strong>and</strong> trends analysis provides forwardlooking<br />
insight for thous<strong>and</strong>s of decision makers.<br />
We are privileged with highly experienced team of Analysts, Researchers <strong>and</strong> Consultants, who use<br />
proprietary data sources <strong>and</strong> various tools <strong>and</strong> techniques to gather, <strong>and</strong> analyze information. Our<br />
business offerings represent the latest <strong>and</strong> the most reliable information indispensable for businesses to<br />
sustain a competitive edge.<br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
90 State Street,<br />
Suite 700,<br />
Albany<br />
NY - 12207<br />
United States<br />
Tel: +1-518-618-1030<br />
USA - Canada Toll Free 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Transparency <strong>Market</strong> Research<br />
15
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Website: http://www.transparencymarketresearch.com/<br />
Browse The <strong>Market</strong> Research Blog :<br />
http://research<strong>and</strong>reports.wordpress.com/ http://www.transparencymarketresearch.com<br />
Transparency <strong>Market</strong> Research<br />
16
Change language